If you're wondering which versions of the COVID-19 virus are currently spreading in the United States, a new surveillance report provides a snapshot. The report looked at trends from May 2023 through September 2024. It found that the virus lineages circulating during that time were primarily descendants of the Omicron variants known as XBB and JN.1. This kind of report is like a weather map for viruses—it shows what's out there and where. It's important to understand what this report is and what it isn't. It summarizes trends in variant proportions based on genetic sequencing. It does not report on how sick these variants make people, whether they cause more severe disease, or how well current vaccines or treatments work against them. The report also doesn't provide specific numbers on how many cases each variant caused. This information helps public health experts monitor the virus's evolution, but it's just one piece of the puzzle for understanding risk.
U.S. surveillance shows XBB and JN.1 Omicron descendants dominated SARS-CoV-2 circulation from May 2023 to September 2024What COVID variants are circulating in the U.S.?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
A surveillance report from the United States tracked SARS-CoV-2 variant circulation from May 2023 to September 2024. The report provided variant proportion estimates, finding that circulating lineages during this period were primarily comprised of descendants of Omicron variants XBB and JN.1. No specific intervention, comparator, or sample size was reported for this descriptive analysis.
No quantitative effect sizes, absolute case numbers, or statistical measures (p-values, confidence intervals) were provided for the reported lineage trends. The report did not include data on clinical outcomes, severity, or transmissibility associated with the identified variants.
Safety, tolerability, and adverse event data were not reported, as this was a surveillance summary rather than a clinical study. The report did not list specific methodological limitations, but its descriptive nature means it cannot establish causality or quantify the public health impact of the observed trends.
For clinical practice, this report provides a snapshot of viral evolution but offers no direct guidance on treatment or prevention. The findings are relevant for understanding the shifting genetic landscape of SARS-CoV-2 but should be interpreted alongside clinical and epidemiological data assessing variant-specific outcomes.